Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0021051 (immunodeficiency)
 71,517 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Human immunodeficiency virus (HIV) infection and the progression to AIDS are characterized by the depletion of CD4(+) T-cells. HIV-1 infection leads to apoptosis of uninfected bystander cells and the direct killing of HIV-infected cells. This is mediated, in part, by the HIV-1 Tat protein, which is secreted by virally infected cells and taken up by uninfected cells. We chemically synthesized two 86-residue subtype D Tat proteins, Ug05RP and Ug11LTS, from two Ugandan patients who were clinically categorized as either rapid progressor or long-term survivor, with non-conservative mutations located essentially in the glutamine-rich region. Structural heterogeneities were revealed by CD, which translate into differing trans-activational and apoptotic effects. CD data analysis and molecular modeling indicated that the short alpha-helix observed in subtype D Tat proteins from rapid progressor patients such as Tat Mal and Tat Ug05RP is not present in Ug11LTS. We show that Tat Ug05RP is more efficient than Tat Ug11LTS in its trans-activational role and in inducing apoptosis in binding tubulin via the mitochondrial pathway. The glutamine-rich region of Tat appears to be involved in the Tat-mediated apoptosis of T-cells.
 ...
PMID:The glutamine-rich region of the HIV-1 Tat protein is involved in T-cell apoptosis. 1533 10

Current antiretroviral therapy protocols enable long-term survival of HIV-infected patients, decreasing the risk of infectious complications. Three classes of anti-HIV treatments are available. With longer survival, unusual cardiovascular complications related to iatrogenic biological anomalies (dyslipidemia and impaired glucose tolerance) have appeared among this young population which is exposed to usual risk factors of atherosclerosis. Antiretroviral therapies are suspected to cause these complications, inducing maturity-onset diabetes in 4 to 20% of patients, impaired glucose tolerance in 15 to 60%, hypertriglyceridemia in 15 to 74% depending on the survey, and hypercholesterolemia in 20 to 60%, especially in case of associated lipodystrophia. A lipid battery including total cholesterol, HDL, and triglycerides, and 12-h fasting blood glucose should be obtained before initiating antiretroviral therapy. Any anomalous finding should be followed carefully with regular surveillance every 3 to 6 months and search for other causes of secondary dyslipidemia. In the event of casual and persisting elevation of LDL-cholesterol levels, a statin treatment can be introduced. For secondary prevention, irrespective of the context, recommendations currently merge with the consensus applying to the general population. These patients require careful surveillance of cardiovascular risk factors and a specific care in addition to treatment of their immunodeficiency.
J Mal Vasc 2004 Oct
PMID:[Antiretroviral therapy and cardiovascular risk]. 1552 82

People with asplenia are at risk for infections due to many causative agents, mainly Streptococcus pneumoniae. Among adults, splenectomy is the most frequent etiology of hyposplenism followed with chronic hematological and connective diseases. Physiopathology of the immunologic impairment due to hyposplenia is multifactorial. Physicians and even patients must be aware of overwhelming sepsis occurring on these conditions. The prognosis of these life-threatening infections is related to the precocity of the treatment onset. These infections, mainly due to S. pneumoniae (50-90% of cases) could be prevented with appropriate precautions. Patients presenting with asplenia must be largely vaccinated against these infectious agents: S. pneumoniae, Haemophilus influenzae b, and possibly Neisseiria meningitidis. Oral phenoxymethylpenicillin seems to be the simplest chemoprophylaxis (despite the global increase of pneumococcal strains with reduced susceptibility). Duration of treatment following splenectomy is discussed: The French medicine agency (AFSSAPS) recommends a 2-year treatment after surgery and for patients having functional hyposplenism (persistency of Howell-Jolly bodies) and/or associated immunodeficiency. Despite these prevention policies, the patient must be informed of the risk of very severe infection.
Med Mal Infect 2004 Nov
PMID:[Prevention and infection in adults patients with hyposplenism]. 1562 52

Despite the wide armamentarium available against the human immunodeficiency virus, the efficacy of therapeutic molecules is reduced by the selection of resistant viral strains. Several data argue in favour of an early control of viral replication ever since the first treatment: the intensity of the initial viral replication, as well as results of studies on antiretroviral drugs given as first line treatment and on the early inhibitory response of viral replication. Although an early control is essential for long-term antiviral success, the optimal time limit for the virologic response still needs to be established early knowledge of the virologic response could prove useful in the evaluation of new and more successful therapeutic combinations. Nevertheless, the impact of an earlier control of viral replication on long-term treatment efficacy and on the prevention of resistance emergence deserves further investigation.
Med Mal Infect 2004 Nov
PMID:[Therapeutic strategies for HIV infection: early response to antiretroviral treatment, predictive factor for the longer term response]. 1590 45

Simplifying therapeutic strategies against human immunodeficiency virus comes first in order to optimise the clinical benefit of long-term antiretroviral treatments for patients. The simplification of dosage and reduction of the number of antiretroviral classes used is expected by patients and physicians alike, as ease of use and reduced restraint improve compliance and quality of life. On the other hand, another priority for simplified treatments is a durable and strong efficacy, together with good tolerance and few long-term complication risks. Nevertheless, the simplification process must not neglect virologic efficacy objectives. Risks of crossed intra-class resistances in case of therapeutic failure must especially be taken intro account. Eventually, new ways of simplification such as NNRTI/boosted PI combinations or boosted PI alone deserve to be thoroughly explored by controlled randomised trials.
Med Mal Infect 2004 Nov
PMID:[Therapeutic strategies for HIV infection: redefining simplification]. 1590 46

New therapeutic strategies aiming at an improved management of patients infected by the human immunodeficiency virus are actually based, at least partly, on older concepts and molecules developed since the discovery of the acquired immunodeficiency syndrome. Accordingly, the first antiretroviral drug available zidovudine, after being left over for some time, now is an active component of tritherapies because of its ability to reduce the emergence of the K65R resistance mutation induced by some nucleosidic reverse transcriptase inhibitors. Similarly, the old concept of inhibiting the virus entry in its target cells, that was once developed with soluble recombined CD4, has been revived in the form of fusion inhibitors, such as the already marketed enfuvirtide, and the currently under phase I development BMS-488043 and SCH-D. Finally, monotherapy, which was abandoned since the advent of the more powerful tritherapies, has now regained interest with the boosted protease inhibitor lopinavir/ritonavir.
Med Mal Infect 2004 Nov
PMID:[Treatment strategies for human immunodeficiency virus infection or "return to the future"]. 1590 47

We report 3 cases of pneumocystis pneumonia (PCP) in 2 female and 1 male patients (mean age=50 years) free of human immunodeficiency virus (HIV) infection. One female patient presented with breast neoplasm the other with Wegener's granulomatosis, the male patient with lymphoma. All patients were taking immunosuppressive treatment at the time of infection. Persistent cough, dyspnea, and severe hypoxemia were the most characteristic clinical signs. All patients presented with lymphopenia (average CD4-cell count=275/mm3), two with hypoalbuminemia, and one with renal failure. In all cases, the microscopic analysis of bronchoalveolar lavage was used to establish the diagnosis. All patients were treated with trimethoprim and sulfamethoxazole and a tapering dose of corticosteroids. Outcome was favorable for 1 patient, 1 was transferred to the intensive care unit for acute respiratory failure, and 1 died.
Med Mal Infect 2007 Sep
PMID:[Pneumocystis pneumonia in 3 non HIV patients]. 1730 85

Human immunodeficiency virus (HIV) positive international travelers are at higher risk of infectious complications. The pretravel assessment often provides an opportunity to update routine vaccinations and HIV patient specific vaccinations including pneumococcus, hepatitis A, hepatitis B, and influenza. Other vaccinations may be required or recommended. Decision for vaccination require considering the risk and severity of the vaccine, preventable diseases in the destination area, the nature of the vaccine (live attenuated vaccines or not), the patient's immune status, and the risk of virological rebound as a consequence of vaccination. The immunogenicity of vaccines is decreased in HIV patient with low CD4 cell counts (above 500 cells per cubic millimetres and particularly above 200 cells per cubic millimetres) and in patients with a persistent HIV RNA viral load. Vaccines should be administered to patients whose HIV infections are in the early stage or in patients receiving HAART with a satisfactory immune status and reduced HIV RNA level. Testing of postvaccination antibodies is useful if serological protective levels are defined. In case of non-response after vaccination, few studies suggest that additional revaccination, increase of vaccine dose, intradermic vaccination, or use of prime-boost combination may be successful. Further research is needed to define vaccination strategies, adapted to the immune status of the HIV patient.
Med Mal Infect 2009 Jan
PMID:[Vaccinations of HIV-infected travelers]. 1872 4

Q fever is a zoonotic disease caused by the ubiquitous pathogen Coxiella burnetii responsible for acute and chronic clinical manifestations. Its geographically heterogeneous prevalence seems mainly related to the clinician interest and the availability of a reference center. Its polymorphic clinical expression imposes reference to diagnosis in presence of pneumonia, hepatitis, prolonged fever or endocarditis with no proof of its etiology. The diagnosis is mainly serological. If acute Q fever is most often benign, endocarditis is constantly fatal without treatment. The treatment is effective and well tolerated, but must be adapted to the acute or chronic pattern, the presence of a heart valve disease, an aneurysm or a vascular prosthesis, an immunodeficiency and the specific problem of pregnancy.
Med Mal Infect 2009 Feb
PMID:[Q fever: current diagnosis and treatment options]. 1901 34

Hypogammaglobulinemia develops in 3 to 6% of patients with thymoma and this association is commonly referred to as thymoma with immunodeficiency (formerly Good syndrome). Recurrent infections with encapsulated bacteria and opportunistic infections associated with disorders of both humoral and cell mediated immunity frequently occur in this rare primary, adult-onset immunodeficiency. We report a case of thymoma with immunodeficiency complicated by disseminated herpes simplex virus (HSV) infection and review five additional cases of HSV-related infections reported since 1966 in patients presenting with thymoma with immunodeficiency. Patients presented with epiglottitis, keratitis, recurrent genital herpes, ulcerative dermatitis, and acute hepatitis. Four of the six cases had a fatal outcome, two of which were directly attributable to HSV infection. Since the risk of invasive opportunistic infections is high and the presentation atypical, lymphocyte count and total serum immunoglobulin should be measured regularly in all patients presenting with thymoma with immunodeficiency.
Med Mal Infect 2009 May
PMID:Thymoma, immunodeficiency, and herpes simplex virus infections. 1926 57


<< Previous 1 2 3 4 Next >>